Skip to main content

Table 1 Baseline data on study subjects

From: Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report

N

 

41

 

Sex

(M/F)

34

(87.2%)

Age

(year)

59.74

(1.29)

BW

(kg)

73.24

(2.50)

BMI

(kg/m2)

26.40

(0.71)

Blood pressure

(SBP/DBP)(mmHg)

141(2.14)/85.5(1.57)

(1.57)

Duration

(year)

16.32

(1.67)

Laboratory data

   

  HbA1c

(%)

8.32

(1.23)

  FPG

(mol/l)

9.72

(0.49)

  LDL-C

(mg/dl)

108.8

(3.41)

  HDL-C

(mg/dl)

48.8

(2.13)

  Triglycerides

(mg/dl)

148.0

(11.72)

  Creatinine

(mg/dl)

0.81

(0.04)

Blood glucose lowering treatment

   

 Insulin

 

1

 

 Insulin+OHA

 

3

 

 OHA

 

32

 

 Diet

 

3

 
  1. F, female; M, male, BMI, Body-mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL-C, High density lipoprotein-cholesterol; LDL-C, Low density lipoprotein-cholesterol; OHA, oral hypoglycemic agent. Data are expressed as means (SEM) or n and %.